|
Wednesday, February 15, 2023, San Francisco, California, 7:15 PM – 8:45 PM Pacific Time (10:15 PM – 11:45 PM Eastern Time)
Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Renal Cell CarcinomaPart 1 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Genitourinary Cancers Symposium
Location
San Francisco Marriott Marquis 780 Mission Street San Francisco, CA 94103 Hotel Phone: (415) 896-1600 Program Schedule — Pacific Time 7:00 PM – 7:15 PM — Registration 7:15 PM – 8:45 PM — Educational Dinner Meeting Meeting Room Yerba Buena – Salon 7 (Lower B2 Level) This event will also be webcast live. Please see Registration tab for details. Faculty
Prof Laurence Albiges, MD, PhD Medical Oncologist Chair, Medical Oncology Department Gustave Roussy Cancer Center Villejuif, France Toni K Choueiri, MD Director, Lank Center for Genitourinary Oncology Department of Medical Oncology Dana-Farber Cancer Institute The Jerome and Nancy Kohlberg Professor of Medicine Harvard Medical School Boston, Massachusetts Thomas Powles, MBBS, MRCP, MD Director of Barts Cancer Institute Queen Mary University of London London, United Kingdom Moderator Brian Rini, MD Professor of Medicine Chief of Clinical Trials Vanderbilt-Ingram Cancer Center Division of Hematology/Oncology Vanderbilt University Medical Center Nashville, Tennessee This activity is supported by educational grants from Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck.
Program Schedule — Pacific Time 7:00 PM – 7:15 PM — Registration 7:15 PM – 8:45 PM — Educational Dinner Meeting MODULE 1: Available Data with and Ongoing Investigation of Immune Checkpoint Inhibitors in Nonmetastatic Renal Cell Carcinoma (RCC) — Prof Powles
MODULE 2: Evidence-Based Selection of First-Line Therapy for Metastatic RCC — Dr Choueiri
MODULE 3: Treatment Options for Relapsed/Refractory RCC — Dr Rini
MODULE 4: Management of RCC Among Special Patient Populations — Prof Albiges
Target Audience
CME Credit Form FACULTY — Prof Albiges and Dr Choueiri have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Prof Powles — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc.MODERATOR — Brian Rini, MD — Advisory Committee and Consulting Agreements: Alkermes, Allogene Therapeutics, Aravive Inc, Arrowhead Pharmaceuticals, Athenex, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Debiopharm, Eisai Inc, EUSA Pharma, Genentech, a member of the Roche Group, Merck, NiKang Therapeutics Inc, Pfizer Inc, Sanofi, Shionogi Inc, Surface Oncology; Contracted Research: Aravive Inc, Arrowhead Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, F Hoffmann-La Roche Ltd, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Surface Oncology; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Stock Options/Ownership — Public Company: PTC Therapeutics; Nonrelevant Financial Relationship: MashupMD — Podcast partnership. RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck. San Francisco Marriott Marquis
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of renal cell carcinoma. IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 6:45 PM PT on Wednesday, February 15th. If you are interested in attending, please visit our registration desk outside the Yerba Buena Ballroom – Salon 7 (Lower B2 Level) at the San Francisco Marriott Marquis hotel (780 Mission Street), within walking distance of the Moscone Convention Center (2 blocks). Please note: Seats will be offered on a first come, first served basis, and onsite registration does not guarantee participation in the meal service.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the 2023 ASCO Genitourinary Cancers Symposium. LIVE WEBCAST registration for all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2023 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. |